Market Segment Analysis

The global Preterm Birth and Prom Testing Market is estimated to be valued at US$ 1.69 billion in 2023 and is expected to exhibit a CAGR of 12.5% over the forecast period 2023 – 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Preterm birth and prom testing includes diagnostic tests that help in the early detection of preterm birth risks and preventive cervical length screening. These tests assess the health of pregnancy and cervix. They help monitor complications and take preventive measures to avoid preterm delivery.

Market key trends:
One of the key trends in the preterm birth and prom testing market is the development and adoption of novel diagnostic technologies. Various technologies such as cervical assessment tools, fetal fibronectin tests, ultrasound examinations, and biomarker tests have been introduced to detect the risks of preterm birth at an early stage. This allows physicians to monitor high-risk patients closely and initiate appropriate treatment. The adoption of advanced testing solutions is expected to drive the market during the forecast period.

Segment Analysis
The global preterm birth and prom testing market is segmented on the basis of test type, end user and region. On the basis of test type, fetal fibronectin test segment dominates the market. Fetal fibronectin test aims at detecting the fibronectin protein in cervicovaginal secretions. It is a highly sensitive and specific test recommended by American Congress of Obstetricians and Gynecologists for detecting the risk of preterm delivery within next 7-14 days. Due to high accuracy of fetal fibronectin test, the segment is expected to continue dominating the market over the forecast period.

Key Takeaways
The global Global Preterm Birth And Prom Testing Market is expected to witness high growth, exhibiting CAGR of 12.5% over the forecast period, due to increasing awareness of early diagnosis of risks associated with preterm birth.

Regional analysis
North America dominates the preterm birth and prom testing market owing to presence of sophisticated healthcare infrastructure, higher adoption of advanced screening tests, and favorable reimbursement policies in the region. The Asia Pacific region is expected to witness fastest growth over the forecast period due to improving healthcare infrastructure and increasing initiatives by key players to expand presence in emerging markets of the region.

Key players
Key players operating in the preterm birth and prom testing market are Abbott Laboratories, Biosynex, Qiagen Sciences LLC, Clinical Innovations LLC, Sera Prognostics, The Cooper Companies Inc., Medixbiochemica, Hologic Inc., IQ Products, NX Prenatal Inc., Promega Corporation, Medical Predictive Technologies Inc., Biosynex, Clinical Innovations LLC, NX Prenatal Inc., Medixbiochemica, Qiagen Sciences LLC, Sera Prognostics Inc., Insight Pharmaceuticals LLC, Creative Diagnostics.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it